Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer's disease patients

Redox Biology

Volumn 12, Issue , 2017, Pages 828-832

  Wilkins, Heather M ^a,b   Koppel, Scott J ^a,b   Bothwell, Rebecca ^b   Mahnken, Jonathan ^b   Burns, Jeffrey M ^a,b   Swerdlow, Russell H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Biomarker; Citrate synthase; Cytochrome oxidase; Mitochondria; Translocase of the outer mitochondrial membrane 40

Indexed keywords

APOLIPOPROTEIN E; CITRATE SYNTHASE; CYTOCHROME C OXIDASE; APOE PROTEIN, HUMAN; APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; APOE GENE; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE CARRIER; ENZYME ACTIVITY; FEMALE; GENE; GENOTYPING TECHNIQUE; HUMAN; MALE; MITOCHONDRIAL DYNAMICS; SINGLE NUCLEOTIDE POLYMORPHISM; CAREGIVER; CYTOLOGY; ENZYMOLOGY; GENETICS; METABOLISM; MITOCHONDRION; THROMBOCYTE;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BLOOD PLATELETS; CAREGIVERS; CITRATE (SI)-SYNTHASE; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HUMANS; MITOCHONDRIA;

EID: 85018572932     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.04.010     Document Type: Article

References (31)

1. [1] Liu, C.C., et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9:2 (2013), 106–118.
2. [2] Roses, A.D., On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J. Alzheimers Dis. 9:3 Suppl (2006), 361–366.
3. [3] Roses, A.D., Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev. Med 47 (1996), 387–400.
4. [4] Roses, A.D., Saunders, A.M., APOE is a major susceptibility gene for Alzheimer's disease. Curr. Opin. Biotechnol. 5:6 (1994), 663–667.
5. [5] Guerreiro, R.J., Gustafson, D.R., Hardy, J., The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol. Aging 33:3 (2012), 437–456.
6. [6] Martin, E.R., et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am. J. Hum. Genet 67:2 (2000), 383–394.
7. [7] Castellano, J.M., et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med., 3(89), 2011, 89ra57.
8. [8] Chang, S., et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. USA 102:51 (2005), 18694–18699.
9. [9] Chen, H.K., et al. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J. Biol. Chem. 286:7 (2011), 5215–5221.
10. [10] Hashimoto, T., et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 32:43 (2012), 15181–15192.
11. [11] Ji, Y., et al. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. Neuroscience 122:2 (2003), 305–315.
12. [12] Kim, J., et al. Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms. Mol. Cells 37:11 (2014), 767–776.
13. [13] Perkins, M., et al. Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E varepsilon4 Carriers. J. Alzheimers Dis. 53:1 (2016), 95–106.
14. [14] Valla, J., et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 22:1 (2010), 307–313.
15. [15] Reiman, E.M., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334:12 (1996), 752–758.
16. [16] Small, G.W., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273:12 (1995), 942–947.
17. [17] Carrieri, G., et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum. Genet. 108:3 (2001), 194–198.
18. [18] Maruszak, A., et al. Mitochondrial haplogroup H and Alzheimer's disease-is there a connection?. Neurobiol. Aging 30:11 (2009), 1749–1755.
19. [19] Roses, A.D., An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch. Neurol. 67:5 (2010), 536–541.
20. [20] Roses, A.D., et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharm. J. 10:5 (2010), 375–384.
21. [21] Roses, A., et al. Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. Alzheimers Dement 12:6 (2016), 687–694.
22. [22] Mahley, R.W., Huang, Y., Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76:5 (2012), 871–885.
23. [23] Swerdlow, R.H., Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal. 16:12 (2012), 1434–1455.
24. [24] Parker, W.D. Jr, Filley, C.M., Parks, J.K., Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40:8 (1990), 1302–1303.
25. [25] Swerdlow, R.H., et al. Cybrids in Alzheimer's disease: a cellular model of the disease?. Neurology 49:4 (1997), 918–925.
26. [26] McKhann, G.M., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:3 (2011), 263–269.
27. [27] Mosconi, L., et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J. Alzheimers Dis. 27:3 (2011), 483–490.
28. [28] Linnertz, C., et al. The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. Alzheimers Dement. 10:5 (2014), 541–551.
29. [29] Roses, A.D., et al. African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles. Alzheimers Dement. 10:6 (2014), 592–601.
30. [30] Minihane, A.M., et al. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc. Nutr. Soc. 66:2 (2007), 183–197.
31. [31] Corder, E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:5123 (1993), 921–923.